With a median follow-up in excess of 5 years, we found no short-term risk of ALT elevation with the use of INSTIs, even after adjusting for confounders including viral hepatitis, BMI, CD4 cell counts, HIV-RNA, dyslipidemia, and diabetes mellitus. Here, CD4 is linked to diabetes mellitus.